转移性激素敏感性前列腺癌的早期治疗强化
本文是《临床肿瘤学杂志》肿瘤学大查房系列文章,通过一例转移性激素敏感性前列腺癌(mHSPC)病例,回顾了ADT联合多西他赛或第二代雄激素受体通路抑制剂(ARPI)的双联强化治疗及三联治疗的试验证据,并基于ARASENS事后分析等近期研究,作者建议对适合化疗者尤其高瘤负荷患者采用三联治疗,对低瘤负荷患者倾向积极使用放疗。
要点
- ADT联合多西他赛或ARPI的双联强化较ADT单药显著改善生存。
- PEACE-1和ARASENS两试验显示三联治疗(ADT+多西他赛+ARPI)的潜力。
- 作者建议适合化疗者尤其高瘤负荷患者采用三联治疗。
核心结论
- 作者建议对适合化疗的mHSPC患者采用三联治疗,尤其高瘤负荷患者;对低瘤负荷患者,在可行时倾向积极使用放疗。
研究设计与样本
- 本文为肿瘤学大查房系列综述,围绕一例mHSPC病例回顾相关文献并总结作者建议的管理方法。
- ARASENS事后分析按疾病体积和疾病风险特征对队列分段,发现三联治疗与改善结局相关,但低体积队列把握度有限。
主要发现
- 过去十年多项试验清楚显示,ADT联合多西他赛或ADT联合第二代口服ARPI的双联强化治疗较ADT单药提供相当大的生存优势。
- 2022年PEACE-1和ARASENS两试验证明在ADT-多西他赛双联基础上加ARPI的三联治疗潜力。
- ARASENS事后分析中,无论按疾病体积还是风险特征分类,三联治疗均与改善结局相关,但低体积队列把握度有限。
关键数值与推荐
- ARASENS事后分析按疾病体积和疾病风险特征分段,原文未报告具体数值。
临床怎么用
- 作者推荐对适合化疗的mHSPC患者采用三联治疗,尤其高瘤负荷患者。
- 作者倾向对低瘤负荷mHSPC患者在可行时积极使用放疗。
- 原文提及正在进行的试验探讨放疗在mHSPC中的作用,此前放疗仅用于局限性疾病或孤立症状性转移。
局限性
- ARASENS事后分析中低体积队列把握度有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in the Journal of Clinical Oncology, to patients seen in their own clinical practice.For generations, oncologists and urologists have used androgen deprivation therapy (ADT) to manage metastatic hormone-sensitive prostate cancer (mHSPC). Until recently, ADT monotherapy was standard. Within the past decade, a series of trials have clearly demonstrated improved outcomes with a more aggressive up-front approach. Doublet intensification therapy, involving either ADT plus docetaxel or ADT plus any of several second-generation oral androgen-receptor pathway inhibitors (ARPIs), provide considerable survival advantages compared with ADT alone. In 2022, two trials, PEACE-1 and ARASENS, demonstrated the potential of triplet therapy, adding an ARPI to an ADT-docetaxel doublet. In the Original Report that accompanies this article, the authors provide a post hoc analysis of ARASENS (ADT plus docetaxel, with or without darolutamide), identifying the subpopulations of patients with mHSPC who might benefit most from a triplet regimen. They segment the ARASENS cohort by disease volume and disease risk profile, finding that triplet therapy is associated with improved outcomes regardless of category (although with limited power in the low-volume cohort). Meanwhile, trials are ongoing examining the role of radiotherapy (RT) in mHSPC, a modality previously reserved for localized disease or isolated, symptomatic metastases. Here, we present a mHSPC case and discuss our approach to mHSPC considering recent studies. We recommend triplet therapy for patients who are suitable candidates for chemotherapy, especially for patients with high-volume disease. We also favor aggressive use of RT, when feasible, for patients with low-volume mHSPC.
引用
- Wala J, Nguyen P, Pomerantz M, et al. Early Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2023. PMID: 37267579. doi:10.1200/JCO.23.00723
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。